newsfilter
← Latest News
Business Wire·

Satellos Bioscience Announces Q1 2024 Financial Results and Operational Highlights

- Conducted preclinical toxicology studies and GMP manufacturing of SAT-3247 - On track to initiate Phase 1 first-in-human clinical trials mid-2024 - Cash balance of $33.2 million at March 31, 2024 - Invited to